We demonstrated that bortezomib when administered at nanomolecular, no toxic doses in combination with suboptimal dose of axitinib, promotes cytotoxic activity both in axitinib-sensitive and -resistant glioma cell lines by increasing p21 protein levels, as supported by the p21 silencing experiments. This evidence concerns the gene CDKN1A and central nervous system cancer.